Skip to main content

The Global Womens Health Market report offers a comprehensive analysis of the Womens Health market with regards to the current and emerging trends, regional outlook, competitive landscape, and forecast estimation for revenue and market share. The report is an all-inclusive document providing important details focusing on growth statistics, estimation of revenue shares and growth, market valuation, and also emphasizes the competitive landscape, business opportunities, and strategic alliances and approaches undertaken by the dominant industry players.

The global women’s health market is expected to reach USD 24.48 Billion by 2027, according to a new report by Emergen Research. The women’s healthcare market is experiencing high demand attributable to a growing demand for devices (intrauterine devices, vaginal rings, and implants) and drugs (Prolia, Evista, Xgeva, Mirena, and Zometa, among others) in applications comprising contraceptives, postmenopausal osteoporosis, hormonal infertility, menopause, endometriosis, and polycystic ovary syndrome (PCOS), among others.

The global Womens Health market report employs an extremely extensive and perceptive process that analyzes statistical data relating to services and products offered in the market. The research study is a pivotal document in understanding the needs and wants of the clients. The report is comprised of significant data about the leading companies and their marketing strategies. The Womens Health industry is witnessing an expansion and change of dynamics owing to the entry of several new players.

The study outlines the rapidly evolving and growing market segments along with valuable insights into each element of the industry. The industry has witnessed the entry of several new players, and the report aims to deliver insightful information about their transition and growth in the market. Mergers, acquisitions, partnerships, agreements, product launches, and joint ventures are all outlined in the report.

Get a sample of the report @

Key Companies Profiled in the Report are:

Merck & Co., Allergan, Bayer AG, Novartis AG, Pfizer, Amgen, Lupin Limited, Johnson & Johnson Services Inc., Agile Therapeutics, and Apothecus Pharmaceutical Corporation

Segments Covered in this report are:

  • Product Type Outlook (Revenue, USD Billion; 2017-2027)
    • Devices
    • Drugs
  • Application Outlook (Revenue, USD Billion; 2017-2027)
    • Contraceptives
    • Postmenopausal Osteoporosis
    • Hormonal Infertility
    • Menopause
    • Endometriosis
    • Polycystic Ovary Syndrome (PCOS)
    • Others
  • End Users Outlook (Revenue, USD Billion; 2017-2027)
    • Hospitals & Clinics
    • Obstetrics & Gynecology Centers
    • Ambulatory Surgical Centers
    • Research Institutes
    • Others

The research report offers a comprehensive regional analysis of the market with regards to production and consumption patterns, import/export, market size and share in terms of volume and value, supply and demand dynamics, and presence of prominent players in each market. 

Regional Analysis Covers:

  • North America (U.S., Canada)
  • Europe (U.K., Italy, Germany, France, Rest of EU)
  • Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)
  • Latin America (Chile, Brazil, Argentina, Rest of Latin America)
  • Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

To know more about the report, visit @

Furthermore, the report provides the analytical data in an organized format segmented into charts, tables, graphs, figures, and diagrams. This enables readers to understand the market scenario in an easy and beneficial manner. Moreover, the report aims to impart a prospective outlook and draw an informative conclusion to assist the reader in making lucrative business decisions. The report, in conclusion, provides a detailed analysis of the segments expected to dominate the market, the regional bifurcation, the estimated market size and share, and comprehensive SWOT analysis and Porter’s Five Forces Analysis.

The modern healthcare market is an ever-changing and rapidly evolving industry, and a key subsector of this market is women’s health. Women’s health is an expansive and multidimensional field that covers a wide array of specialized facets and subspecialties, such as gynecology and obstetrics, menstrual issues, fertility, and menopause, among others. Due to its varied approach and specialized focus, the women’s health market has several major players and a highly competitive landscape. This article will discuss the key players in the women’s health market, their competitive strategies, growth patterns, statistics, and revenue.

Some of the most influential players in the women’s health market include Mylan, Bayer Healthcare, Pfizer, Merck, and Novartis. Mylan is the largest generics manufacturer and has seen notable success in the women’s health segment. A twofold strategy focusing on harnessing both generic drugs and specialty products has enabled Mylan to develop an extensive portfolio in this space. Bayer Healthcare is one of the leading players in the women’s health market, employing a strategy of customer-oriented innovation, backed by a comprehensive R&D program and links to universities and health centers. Pfizer and Merck both employ innovative strategies, leveraging digital platforms and data-driven approaches to better understand and address customer requirements. Finally, Novartis is notable for its combination of both digital and physical approaches to customer engagement and product development.

In terms of growth patterns, the women’s health market has seen significant increases in both global and regional levels. According to recently released figures, the global market is estimated to grow at a compound annual growth rate (CAGR) of 8.7% between 2018 and 2023, while the regional markets have seen more impressive growth rates, such as the Europe and North America markets, which have reported a CAGR of 10.6% and 9.5%, respectively.

Advanced technologies, such as artificial intelligence and robotics, have greatly aided the women’s health industry in terms of metrics, tracking, and marketing, while recent advancements in drug delivery devices and pharmaceutical formulation have also had a significant positive impact. Furthermore, collaborations between key players and governments have helped to foster a better understanding of customer needs and expectations.

In terms of market revenue and statistics, the women’s health market size was estimated to be around USD 68.25 billion in 2018 and is estimated to reach over USD 106.45 billion by 2023. This remarkable growth is attributed to the rising prevalence of gynecological, fertility, and other health issues, in addition to the increased demand for more effective and specialized treatments.

To conclude, the women’s health market is a rapidly evolving subsector of the wider healthcare industry. Several key players, such as Mylan, Bayer, Pfizer, Merck, and Novartis, are competing for market share through ambitious strategies, which have helped to fuel the remarkable growth figures seen in recent years. With advanced technology and collaborations, we can expect the market to see further increases in both revenue and statistics.

Leave a Reply

Close Menu

Wow look at this!

This is an optional, highly
customizable off canvas area.

About Salient

The Castle
Unit 345
2500 Castle Dr
Manhattan, NY

T: +216 (0)40 3629 4753
E: [email protected]